Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45

    NEXT STORY
    NuGenerex Immuno-Oncology Announces Shareholder Conference Call July 10, 2020 at 4:15 PM
    PREV STORY
    Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Bendcare Endorses Vectra® Testing for Patients with Rheumatoid Arthritis

    Vectra Provides Important Information to Help Rheumatologists Identify Patients at Increased Risk of Joint ...

    author_avatar
    NASDAQ Market News

    Crown Bioscience Announces Collaboration to Develop Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Antibody

    SANTA CLARA, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary ...

    author_avatar
    NASDAQ Market News

    Exalenz Bioscience’s Non-Invasive BreathID® Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH

    Studies will use BreathID 13C-methacetin breath test to evaluate patient response to therapy MODI’IN, ...

    author_avatar
    NASDAQ Market News